ARCHIVES

Genetics Flexes Muscle At AACR Annual Meeting, Joint Session With ASCO On Genetic Charges

This article is from The Cancer Letter archive.

Vol. 17 No. 21 | May 24, 1991

Download PDF Visit The Full Archive

Related Articles

Major Changes Being Considered By NCI For FCRA

April 14, 1978

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Wittes, Group Chairmen Agree On Payment Per Case, Other Methods To Increase Patient Accrual

August 21, 1987

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

July 26, 2013

IOM Calls FDA Advisory System Sounds, Suggests Conflict Criteria Changes

March 5, 1993

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014